• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

Cannabinoid treatment developer SciSparc raises $8.15M

March 5, 2021 By Sean Whooley

SciSparcSciSparc (OTCQB:SPRCY), formerly Therapix Biosciences, announced today that it closed a private placement worth $8.15 million.

Tel Aviv, Israel-based SciSparc sold nearly 1.2 million units in the offering, with 916,316 units (consisting of 1 American Depositary Share, one Series A warrant to purchase an equal number of units purchased and one Series B warrant to purchase half the number of units) sold at an offering price of $7.07 per unit.

Additionally, the offering included 236,312 pre-funded units at $7.069 per unit. The Series A warrants have an exercise price of $7.07, while the Series B warrants are priced at $10.60. Both are exercisable six months from the date of issuance and have a term of exercise equal to five years from the initial exercise date.

Aegis Capital acted as the exclusive placement agent in the U.S. in connection with the offering.

SciSparc develops cannabinoid pharmaceuticals with a focus on treatments for Tourette syndrome, obstructive sleep apnea, pain management, autism spectrum disorder and epilepsy. The drugs can be delivered through a nasal delivery platform the company sub-licensed through a deal with Yissum in 2017.

Filed Under: Business/Financial News, Drug-Device Combinations, Featured, Funding Roundup, Pharmaceuticals Tagged With: SciSparc, Therapix Biosciences

IN CASE YOU MISSED IT

  • Omnipod 5 rollout for type 2 rolls on as Insulet pursues next-gen automation
  • LifePlus reports clinical validation of non-invasive glucose, blood pressure monitor
  • Abbott Diabetes head talks Medtronic partnership, exciting times ahead
  • PharmaSens, SiBionics innovatively combine tech in all-in-one insulin patch pump
  • Study backs Biolinq intradermal sensor in muscle loss prevention during GLP-1 therapy

About Sean Whooley

Sean Whooley is an associate editor who mainly produces work for MassDevice, Medical Design & Outsourcing and Drug Delivery Business News. He received a bachelor's degree in multiplatform journalism from the University of Maryland, College Park. You can connect with him on LinkedIn or email him at swhooley@wtwhmedia.com.

Primary Sidebar

“ddb
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in drug delivery.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing + Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy | RSS